[1] 中华医学会肝病学分会, 中华医学会传染病与寄生虫病学分会. 丙型肝炎防治指南[J]. 中华传染病杂志, 2004, 22(2): 131-136. [2] 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2022年版)[J]. 中华传染病杂志, 2023, 41(1):29-46. [3] 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2015年版)[J/CD]. 中国肝脏病杂志(电子版), 2015, 8(3):19-35. [4] 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 中华传染病杂志, 2020, 38(1):9-28. [5] PAWLOTSKY JM, NEGRO F, AGHEMO A, et al.EASL recommendations on treatment of hepatitis c: final update of the series[J]. J Hepatol, 2020, 73(5): 1170-1218. [6] WORLD HEALTH ORGANIZATION.Global health sector strategy on viral hepatitis 2016-2021[M]. Geneva: World Health Organization,2016. [7] ZHAO Z, CHU M, GUO Y, et al.Feasibility of hepatitis c elimination in china: from epidemiology, natural history, and intervention perspectives[J]. Front Microbiol, 2022, 13: 884598. [8] 陈园生, 李黎, 崔富强, 等. 中国丙型肝炎血清流行病学研究[J]. 中华流行病学杂志, 2011, 32(9): 888-891. [9] 李杰, 陈杰, 庄辉. 丙型肝炎的流行病学[J]. 实用肝脏病杂志, 2012, 15(5): 379-381. [10] GOWER E, ESTES C, BLACH S, et al.Global epidemiology and genotype distribution of the hepatitis c virus infection[J]. J Hepatol, 2014, 61(1): S45-S57. [11] BLACH S, TERRAULT NA, TACKE F, et al.Global change in hepatitis c virus prevalence and cascade of care between 2015 and 2020: a modelling study[J].Lancet Gastroenterol Hepatol, 2022, 7(5): 396-415. [12] 中联肝健康促进中心, 中华医学会肝病学分会, 中华医学会检验医学分会, 等. 中国丙型病毒性肝炎院内筛查管理流程(试行)[J]. 中华肝脏病杂志, 2021, 29(4): 319-325. [13] WORLD HEALTH ORGANIZATION. Updated recommendations on HCV simlified service delivery and HCV diagnostics:policy brief[M]. Geneva: World Health Organization, 2022. Licence: CC BY-NC-SA 3.0 IGO. [14] YOUNOSSI ZM, STEPANOVA M, FELD J, et al.Sofosbuvir/velpatasvir improves patient-reported outcomes in hcv patients: results from astral-1 placebo-controlled trial[J]. J Hepatol, 2016, 65(1): 33-39. [15] YOUNOSSI ZM, STEPANOVA M, SULKOWSKI M, et al.Ribavirin-free regimen with sofosbuvir and velpatasvir is associated with high efficacy and improvement of patient-reported outcomes in patients with genotypes 2 and 3 chronic hepatitis c: results from astral-2 and -3 clinical trials[J]. Clin Infect Dis, 2016, 63(8): 1042-1048. [16] 国家医疗保障局. 国家基本医疗保险、工伤保险和生育保险药品目录.(医保发〔2021〕50号)[EB/OL].[2021-12-03].http://www.nhsa.gov.cn/art/2021/12/3/art_37_7429.html. [17] CHENG PN, MO LR, CHEN CT, et al.Sofosbuvir/velpatasvir for hepatitis c virus infection: real-world effectiveness and safety from a nationwide registry in taiwan[J]. Infect Dis Ther, 2022, 11(1): 485-500. [18] JI F, LI J, LIU L, et al.High hepatitis c virus cure rates with approved interferon‐free direct‐acting antivirals among diverse mainland chinese patients including genotypes 3a and 3b[J]. J Gastroenterol Hepatol, 2021, 36(3): 767-774. [19] 付小义, 金娴, 徐晓婧, 等. 泛基因型DAA治疗慢性丙型肝炎[J/CD]. 新发传染病电子杂志,2018,3(1):30-33. [20] LEPIDA A, COLOMBO M, FERNANDEZ I, et al.Final results of the telaprevir access program: fibroscan values predict safety and efficacy in hepatitis c patients with advanced fibrosis or cirrhosis[J]. PLOS ONE, 2015, 10(9): e0138503. [21] LIU CH, CHEN CY, SU WW, et al.Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis c virus infection and severe renal impairment[J]. Gut, 2022, 71(1): 176-184. [22] YU ML, HUANG CF, WEI YJ, et al.Establishment of an outreach, grouping healthcare system to achieve microelimination of hcv for uremic patients in haemodialysis centres (erase-c)[J]. Gut, 2021, 70(12): 2349-2358. [23] BOURLIÈRE M, GORDON SC, FLAMM SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated hcv infection[J].N Engl J Med, 2017, 376(22): 2134-2146. |